Most sold healthcare stocks in Q4 2019

See which Healthcare stocks institutional investors trimmed or exited the most in Q4 2019, measured as net reductions in reported share positions from Q3 2019 into Q4 2019. Notable reductions at the top of this list include ASTRAZENECA PLC-SPONS ADR (AZN), HOLOGIC INC (HOLX), TAKEDA PHARMACEUTIC-SP ADR (TAK), JOHNSON & JOHNSON (JNJ). These rankings are based on SEC 13F filings from the investors we track.

SymbolNameNet sharesNet valueNewAddedTrimmedSold outHolding now
AZNASTRAZENECA PLC-SPONS ADR-10,161,310-$244.81K01102
HOLXHOLOGIC INC-9,682,163-$725.07K01203
TAKTAKEDA PHARMACEUTIC-SP ADR-9,157,218-$146.09K01112
JNJJOHNSON & JOHNSON-4,842,577-$274.92K156015
AKBAAKEBIA THERAPEUTICS INC-4,804,900$42.05K01103
TEVATEVA PHARMACEUTICAL-SP ADR-3,389,321$208.55K01215
CNCCENTENE CORP-2,947,357$157.78K01305
CVSCVS HEALTH CORP-2,607,682$260.89K346013
IQVIQVIA HOLDINGS INC-2,425,202-$334.73K00304
SNYSANOFI-ADR-1,813,472$144.62K01103
MRNAMODERNA INC-1,356,026-$9.50K00101
FOLDAMICUS THERAPEUTICS INC-1,340,946-$10.53K00101
ZBHZIMMER BIOMET HOLDINGS INC-1,040,051-$122.60K10415
GOSSGOSSAMER BIO INC-967,171-$15.87K00010
ILMNILLUMINA INC-953,438-$242.70K12104
HQYHEALTHEQUITY INC-857,812-$47.49K00101
NVSTENVISTA HOLDINGS CORP-814,828-$20.72K00111
ELVELEVANCE HEALTH INC-787,986$584.27K224110
LLYELI LILLY & CO-761,301$90.21K02113
VEEVVEEVA SYSTEMS INC-CLASS A-646,010-$106.52K00101
EXASEXACT SCIENCES CORP-637,786-$53.27K00111
TNDMTANDEM DIABETES CARE INC-608,727-$35.47K00101
REGNREGENERON PHARMACEUTICALS-596,318$41.51K01304
CTLTCATALENT INC-586,262-$13.64K01213
GMABGENMAB A/S -SP ADR-547,078-$9.54K00202
ANABANAPTYSBIO INC-483,805-$18.66K10011
OSURORASURE TECHNOLOGIES INC-426,290-$83800101
EDITEDITAS MEDICINE INC-403,021$26.99K10103
AMGNAMGEN INC-389,778$139.90K12407
EHCENCOMPASS HEALTH CORP-359,922-$22.62K01011
SRPTSAREPTA THERAPEUTICS INC-348,078-$26.22K00010
LNTHLANTHEUS HOLDINGS INC-230,100-$12.17K00101
EBSEMERGENT BIOSOLUTIONS INC-220,210-$10.24K00101
CAHCARDINAL HEALTH INC-214,670$11.25K11204
EWEDWARDS LIFESCIENCES CORP-208,362-$16.62K24209
RVNCREVANCE THERAPEUTICS INC-198,900-$39800101
LGNDLIGAND PHARMACEUTICALS-198,225-$14.88K00101
HAEHAEMONETICS CORP/MASS-187,084-$51.02K00101
WATWATERS CORP-177,011$16.26K00212
ABUSARBUTUS BIOPHARMA CORP-168,312-$25700010
GMEDGLOBUS MEDICAL INC - A-167,386-$19200101
ADUSADDUS HOMECARE CORP-159,020-$12.61K00010
SAGESAGE THERAPEUTICS INC-152,875-$28.98K10011
ALLKALLAKOS INC-151,500-$11.72K00101
ESPRESPERION THERAPEUTICS INC-141,900-$5.20K00010
NVSNOVARTIS AG-SPONSORED ADR-129,781$442.09K13209
AGIOAGIOS PHARMACEUTICALS INC-121,000-$3.92K00010
NEONEOGENOMICS INC-119,500-$2.29K00010
ATRAPTARGROUP INC-117,361-$13.91K10011
CRONCRONOS GROUP INC-100,000-$90400010
20 symbols with net change in reported shares from tracked managers.−11.2M−8.4M−5.6M−2.8M0.00Net change in reported shares (tracked managers)AZNHOLXTAKJNJAKBATEVACNCCVSIQVSNYMRNAFOLDZBHGOSSILMNHQYNVSTELVLLYVEEVSymbol

Frequently asked questions about Most sold healthcare stocks in Q4 2019

  • What are the most sold Healthcare stocks in Q4 2019?

    The most sold healthcare stocks in Q4 2019 are those with the largest decrease in reported share counts across tracked institutional investors compared to Q3 2019, based on SEC 13F filings.

  • Which healthcare stocks did institutional investors trimmed or exited the most in Q4 2019?

    Among the managers we track, net reductions were largest in companies such as ASTRAZENECA PLC-SPONS ADR (AZN), HOLOGIC INC (HOLX), TAKEDA PHARMACEUTIC-SP ADR (TAK), based on aggregated 13F data.

  • How is institutional selling calculated?

    Selling is calculated by summing the net decrease in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q3 2019).

  • Does this include all institutional owners?

    These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.

  • Are these trades real-time?

    No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.